Mutational Reactivities for Cancer Regression

P

Peter Attia MD hosts a discussion with Steve Rosenberg.

ImmunityMedical

Quotes From Source

“Unique mutational reactivities can cause solid epithelial cancers to respond.”

Story of claim

Utilizing mutational reactivities can make 90% of solid epithelial cancers respond to immunotherapy, potentially leading to regression.

  • Goal: To utilize mutational reactivities for cancer regression via immunotherapy.
  • Proof: Mutational reactivities can be harnessed to make solid epithelial cancers responsive to immunotherapy.
  • Nuances:
    • Solid epithelial cancers result in 90% of cancer deaths
    • The aim is to make them respond to immunotherapy
  • Impact on Life: Potential to significantly reduce cancer mortality rates by targeting mutational reactivities.

Investments

  • Price: Varies, often covered by clinical trials
  • Time: Ongoing research; clinical application may take years
  • Effort: Involves long-term commitment to treatment and research participation

Risks

Currently experimental; responses may vary widely among patients.

Alternatives

  • Participation in other clinical trials
  • Standard cancer treatments

Get Started 🚀

  • Seek entry into relevant clinical trials
  • Consult with research institutions on eligibility
  • Stay informed on latest research advancements

Brogevity AI can make mistakes. Check important info.

Reference Video